Press Release
Axoltis Pharma presents promising results from phase 1b clinical trial of innovative drug candidate for neurodegenerative diseases
- Good safety profile and significant pharmacological effects confirmNX210c drug candidate properties and potential to address broad range of neurodegenerative diseases
- Biomarkers reveal significant and sustained effects confirming NX210c’saction on integrity and repair of Blood Brain Barrier (BBB), as well as fundamental pathways in neuroprotection and neurotransmission
- In 2024, Axoltis plans to initiate phase 2 trial in patients with Amyotrophic Lateral Sclerosis (ALS) and conduct phase 1b trial in Parkinson’s Disease(PD) while performing in silico modeling to further evaluate and optimize potential of NX210c more broadly in neurodegenerative diseases
